Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonic anhydrase 5B, mitochondrial (CA5B), is a mitochondrial enzyme that catalyzes the reversible conversion of carbon dioxide to bicarbonate, using a zinc ion as a cofactor[1][2][3][5][9]. CA5B is distributed across a wide range of tissues including brain, liver, kidney, muscle, and pancreas, and plays roles in intermediary metabolism and maintenance of acid-base balance[1][2]. It is a member of the carbonic anhydrase family, which comprises zinc metalloenzymes involved in various physiological processes. Inhibition can disrupt key metabolic pathways and has been linked to altered mitochondrial function, with clinical interest in certain metabolic disorders[1][3]. Multiple drugs, including some thiazide diuretics and anticonvulsants, have inhibitory activity against CA5B[3].
Inhibition of mitochondrial carbonic anhydrase activity (block reversible conversion of CO₂ to bicarbonate, impacting intermediary metabolism and acid-base balance)[3][5]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbonic anhydrase 5B, mitochondrial (CA5B).